The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
about
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCopd.Disease knowledge level is a noteworthy risk factor of anxiety and depression in patients with chronic obstructive pulmonary disease: a cross-sectional study.The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.Salmeterol combined with fluticasone propionate improved COPD in patients during stable stage.Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.Health status in the TORCH study of COPD: treatment efficacy and other determinants of change.Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPDRelationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in COPD.Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled studyComparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease.What is the difference between FEV1 change in percentage predicted value and change over baseline in the assessment of bronchodilator responsiveness in patients with COPD?Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.Treating patients with respiratory disease who smoke.Long-term therapy in COPD: any evidence of adverse effect on bone?The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease.Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis.Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.Minimal clinically important differences in pharmacological trials.Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis.Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials.Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis.Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
P2860
Q24197853-A54A13C2-38B5-4444-9867-3CAD62687EEFQ31016356-41769AE5-3E38-4194-9FA2-45E51383F4E3Q33700654-7CB42ED2-9C91-423E-8277-C0DA6F14C813Q33966009-5AB29E34-1E11-4E77-B9A5-DFFFD5CDA610Q34415156-564763DE-0AC2-4CE1-9696-88448AE0C89AQ34888769-2D175734-0647-4B0C-8828-9894095E99C1Q35052737-AE5B8F0D-1A37-4557-B02C-F76801CB4D51Q35492192-656B00A3-5EC1-4FD2-BBC7-73FF2D514047Q35602749-EBE17628-4046-4B65-AE84-9076982CA943Q35838660-4C333421-33EC-4247-B563-15D0EA140066Q36036894-61F1FA13-9D04-4081-A3F9-689B809792BAQ36116549-9339719B-EC63-46AD-8742-0B6A213A14E5Q36982645-A2D007DA-947A-4C22-8F19-06E7E0FB9267Q37127999-D1A260BC-C5AC-4BF9-A642-E43FF936801EQ37271761-987E3300-F4DA-414C-BB20-BDFDEBC39532Q37362600-8E0A207F-91C2-471E-ADFF-40A581B0B50FQ37408472-6EDA2800-6216-42D7-AAAC-1A4EB534FDB4Q37748948-6B2F7A4D-F9B6-4D79-9D1D-A6C54DB488D9Q37864538-2B499932-8DEA-4388-B010-A365701BEA8CQ37890024-26412BCC-A417-4C80-9615-AC9A13CE41E5Q37893470-3A4344CF-D5A0-462D-8160-A7DC8DF0C35BQ38175163-0C75876E-5CA4-44D9-9FB4-905F09075F74Q38215747-D8289C2C-16AB-4DA8-ADC5-D18DF881C90EQ38604595-23369BFA-3321-4310-89B2-FCA74DBD5461Q40132336-7612C75E-42BE-442C-81EE-60742A4E5605Q42044652-D4E37DD6-61DE-4A2A-82EA-3B98193A602BQ57817177-8A535A28-AC7C-48CC-B90F-015E5FAB7812
P2860
The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The efficacy and safety of com ...... in Chinese patients with COPD.
@en
type
label
The efficacy and safety of com ...... in Chinese patients with COPD.
@en
prefLabel
The efficacy and safety of com ...... in Chinese patients with COPD.
@en
P2093
P356
P1433
P1476
The efficacy and safety of com ...... in Chinese patients with COPD.
@en
P2093
Chang-Zheng Wang
Guang-Fa Wang
Jin-Ping Zheng
Nan-Shan Zhong
Shao-Guang Huang
Sheng-Dao Xiong
Tie-ying Sun
Wen-Jie Huang
P304
P356
10.1378/CHEST.06-3009
P407
P577
2007-10-20T00:00:00Z